Kauliv

Teriparatide, the active ingredient in Kauliv, is a Parathyroid hormone analog presented as a subcutaneous injection for subcutaneous use. It is indicated for the treatment of postmenopausal osteoporosis, male osteoporosis at high risk of fracture, and glucocorticoid‑induced osteoporosis.

GNH USA supplies Kauliv as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU quality standards and provides reliable logistics for global distribution.

Teriparatide is used in bone‑metabolism disorders to increase bone mass and reduce fracture risk.

- Postmenopausal osteoporosis: improves bone mineral density and lowers vertebral and non‑vertebral fracture incidence. - Male osteoporosis at high risk of fracture: enhances bone strength and helps prevent skeletal fractures. - Glucocorticoid‑induced osteoporosis: counteracts bone loss caused by long‑term glucocorticoid therapy.

Teriparatide may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate feeling of sickness. - Headache: transient head discomfort. - Dizziness: occasional light‑headedness. - Injection site reactions: pain, redness, or swelling at the injection site. - Fatigue: general tiredness.

Serious or Rare Side Effects: - Hypercalcemia: elevated blood calcium levels that may cause symptoms. - Osteosarcoma: a rare bone tumor observed in long‑term animal studies. - Severe hypotension: marked drop in blood pressure after injection.

When prescribing Kauliv, clinicians should consider several safety measures.

- Patient selection: assess calcium levels and renal function before initiating therapy. - Monitoring: regular bone density scans and serum calcium measurements are recommended. - Contraindications: avoid in patients with active malignancy involving bone or prior radiation therapy to the skeleton. - Duration of therapy: limit treatment to the approved period (typically up to 24 months) to reduce risk of rare adverse events. - Pregnancy and lactation: use only if potential benefit justifies potential risk; data are limited. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Teriparatide can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Hypercalcemia‑inducing agents (e.g., high‑dose vitamin D, calcium supplements): may exacerbate serum calcium rise. - Bisphosphonates administered concurrently: may blunt the anabolic effect of teriparatide. - Radiopharmaceuticals targeting bone: increased risk of osteosarcoma.

Moderate Interactions (Monitor Closely): - Loop diuretics: can affect calcium balance, monitor serum calcium. - Corticosteroids: may reduce therapeutic benefit, monitor bone density. - Antacids containing aluminum or magnesium: may interfere with calcium absorption.